Forxiga generics take over 30% of market in 6 mths
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.10.21 05:50:55
가나다라
0
Cumulative prescriptions of Foxiga and Xigduo generics in Q3 amount to KRW 10.6 billion… original drug occupies KRW 25.3 billion of market
Only 5 generic companies earned over KRW 2 bil in Q2, Q3…Cumulated sales made by each of the 50 companies amount to less than KRW 30o million
Generic versions of ‘Forxiga (dapagliflozin)’ have increased their share in the market to 30% in half a year since the original Forxiga’s patent expiry.
Since April of last year, 63 companies have been fiercely competing in the market after concurrently releasing their respective generic versions, and Boryung Pharmaceutical, Hanmi Pharm, Aju Pharm, Kyung Dong Pharma, and Daewon Pharmaceutical have recorded cumulative prescriptions worth more than KRW 1 billion in Q2 and Q3.
On the other hand, 50 (79%) of the 63 companies that released generics posted cumulative prescriptions of less than KRW 300 million.
Forxiga market increases from KRW 24.9 bil to KRW 35.
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)